Feist-Weiller, Caris Life Sciences partner to provide advanced technology to cancer patients -
Doctors Cancer Center LSU Health Shreveport Feist-Weiller will now have access to innovative precision Medicine the technology that determines the unique biological characteristics of the cancerous tumor of each individual patient. Once the information is known, doctors can identify chemotherapy or radiation therapy regimens tailored to attack. The new capacity is the result of the emerging technology known as tumor profiling. Feist-Weiller work with Caris Life Sciences to provide advanced technology to patients with cancer of the University Health Shreveport, a clinical partner of the Health School of Medicine LSU Shreveport.
first clinical molecular profiling program in the region will use Caris' leading service industry overall profiling of the tumor molecular Caris Intelligence ™ , to enhance the expertise clinical and research Feist-Weiller Cancer Center. It will expand the approach to personalized medicine clinic and provide a more precise treatment plan for patients. The partnership with Caris also includes clinical support, and patient education and physician integration system. It also creates a forum to pursue joint research opportunities.
"As the only institution within 250-mile offer these capabilities, our partnership with Caris is essential to provide specific, personalized care for cancer patients in our center every year," said Glenn Mills, MD FACP, Professor and Director of Feist-Weiller Cancer Center. "this type of technology is integral to better understand the unique molecular features of the disease of a patient, allowing a more targeted treatment planning . "
Cherie-Ann O. Nathan, MD, FACS, Chair and Professor, Director of Head and Neck Oncology and Surgical Research, believes that molecular profiling program will not only raise the level of clinical care for patients, but also of the Center research programs.
"Organ preservation using radiation therapy with or without chemotherapy is often used as an alternative to surgery for the disease at an advanced stage. However, radiation resistance in the head and neck often results in the lack of response to treatment, "said Dr. Nathan." Feist-Weiller Cancer Center is the first to Molecularly resistant genes with radiation profile for Caris identify potential patients who can not benefit from radiation treatment or benefit from alternative radiosensitizing chemotherapy. "
in recent years, molecular profiling has become a valuable tool for oncologists to take treatment decisions for patients with difficult treatment and / or rare and aggressive cancers. Caris molecular Intelligence correlates molecular data of a tumor with biomarker associations / drug the last clinical and scientific literature on cancer. This information is used to recommend more or less likely to benefit the patient treatment. It will also identify potential clinical trials to the patient. The system utilizes analysis of traditional pathology methods, and more recently developed DNA sequencing technologies.
"Every day oncologists in making critical decisions about clinical care that require the most accurate, reliable and feasible, based on each single tumor patients," said David D. Halbert, Chairman -Director General of Caris Life Sciences. "As a leader in the profiling of the complete tumor for cancer, we are pleased to work with Feist-Weiller Cancer Center at LSU and their experts to create a molecular profiling program that will offer these advanced process information - information which may help patients better control their disease. "
EmoticonEmoticon